Open-house discount agreements for adalimumab 2026–19

Summary

Participating health insurers are seeking rebate agreements for adalimumab under an open-house procedure. The agreements cover the relevant finished medicinal products and generally run for up to 24 months, starting no earlier than 1 January 2027 and ending no later than 31 December 2028. All eligible pharmaceutical companies may join during the contract period; the insurers offer uniform terms and do not grant exclusivity.